Jazz Pharmaceuticals acquires Actio Biosciences for $820M (September 2026)
Jazz Pharmaceuticals completed its acquisition of Actio Biosciences on 15 September 2026 (Jazz Ex. 99.1 close PR). Upfront consideration was $820 million.
Source: https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/jazz-20260915.htm